Bone Marrow-on-a-Chip Developed to Test Drug Effects - - BioPharm International


Bone Marrow-on-a-Chip Developed to Test Drug Effects

BioPharm International
Volume 27, Issue 6, pp. 50

Researchers f rom Harvard’s Wyss Institute for Biologically Inspired Engineering have reproduced the structure, functions, and cellular make-up of bone marrow, to create a device known as “bone marrowon-a-chip.” The device could give scientists a tool to test the effects of new drugs and toxic agents on whole bone marrow. The researchers packed dried bone powder into an open, ring-shaped mold the size of a coin battery, and implanted the mold under the skin of a mouse’s back. After eight weeks, the disk-shaped bone that had formed in the mold was surgically removed and examined with a CAT scanner. The scan showed a honeycomb-like structure that looked identical to natural trabecular bone. When the stained tissue was examined under a microscope, the marrow was packed with blood cells, just like marrow from a living mouse. In addition, when the researchers sorted the bone marrow cells by type, the mix of different types of blood and immune cells in the engineered bone marrow was identical to that in a mouse thighbone.

To sustain the engineered bone marrow outside of a living animal, the researchers surgically removed the engineered bone from mice, then placed it in a microfluidic device that steadily supplied nutrients and removed waste to mimic the circulation the tissue would experience in the body. Marrow in the device remained healthy for up to one week, long enough to test the toxicity and effectiveness of a new drug. Similar to marrow from live mice, this engineered marrow was also susceptible to radiation, but an FDA-approved drug that protects irradiated patients also protects the marrow on the chip. According to the study, the device could be used to develop safe and effective strategies to prevent or treat radiation’s lethal effects on bone marrow without resorting to animal testing. Bone marrow-on-a-chip could also be used to maintain a cancer patient’s own marrow temporarily while undergoing marrow-damaging treatments. The report is featured in the May 2014 online issue of Nature Methods.

blog comments powered by Disqus



First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here